Table 3 Recent integrin-targeting drugs intended as disease therapies in ongoing clinical studies (2019–2022)
From: Targeting integrin pathways: mechanisms and advances in therapy
Disease | Targeted integrins | Drug name | Source | Drug types | Time (first posted) | Study status |
|---|---|---|---|---|---|---|
Ulcerative colitis and Crohn’s disease | α4β7 | MORF-057 | NCT05291689 | Small molecule | 2022-03-23 | Phase II |
PN-10943 | NCT04504383 | Small molecule | 2020-08-07 | Phase II | ||
Solid tumors | αvβ3 | Antiangiotide | CTR20150368; CTR20200847 | Peptide | 2015-07-20 2020-08-28 | Phase I |
BGC-0222 | CTR20221496 | Peptide drug conjugate | 2022-06-16 | Phase I | ||
ProAgio | NCT05085548 | Novel proteins synthesized by computer simulation | 2021-10-20 | Phase I | ||
αvβ5 | CEND-1 | NCT05042128; NCT05052567; NCT05121038; CTR20212588 | Peptide | 2021-09-13 2021-09-22 2021-11-16 2021-10-22 | Phase II | |
Pan-αv | HYD-PEP-06 | CTR20220769 | Small molecule | 2022-04-14 | Phase II | |
αLβ2; α4β1; | 7HP-349 | NCT04508179 | Small molecule | 2020-08-11 | Phase I | |
β6 | SGN-B6A | NCT04389632 | Antibody drug conjugate | 2020-05-15 | Phase I | |
α3β1; α5β1 | ABBV-382 | NCT04554966 | Antibody | 2020-09-18 | Phase I | |
β1 | OPC-415 | NCT04649073 | CAR T-cell therapy | 2020-12-02 | Phase II | |
Relapsed and/or refractory multiple myeloma | β7 | MT-1002 | NCT04723186 | Peptide | 2021-01-25 | Phase II |
Acute coronary syndrome patients with PCI | αIIbβ3 | Zalunfiban | NCT04825743 | Small molecule | 2021-04-01 | Phase III |
AXT-107 | NCT04697758; NCT04746963 | Peptide | 2021-01-06 2021-02-10 | Phase I/II | ||
Diabetic macular edema/neovascular age-related macular degeneration/dry eye disease | αvβ3; α5β1 | THR-687 | NCT05063734 | Small molecule | 2021-10-01 | Phase II (Terminated) |
pan-αv; α5β1 | AG-73305 | NCT05301751 | Fusion protein | 2022-03-31 | Phase II | |
LFA-1A | VVN-001 | NCT04556838; CTR20211530 | Small molecule | 2020-09-21 2021-07-01 | Phase II | |
Imaging diagnosis | αvβ3 | 99mTc-3PRGD2 | CTR20191465; NCT04233476 | Imaging agent | 2019-07-30 2020-01-18 | Phase III |
αvβ3 | Alfatide[18F] | CTR20213024 | Imaging agent | 2021-12-10 | Phase III | |
[68Ga]-FF58 | NCT04712721 | Imaging agent | 2021-01-15 | Phase I | ||
αvβ3/αvβ5 | 99mTc- RWY | NCT04289532 | Imaging agent | 2020-02-28 | Early Phase I | |
α6 | [18F]FBA- A20FMDV2 | NCT04285996 | Imaging agent | 2020-02-26 | N/A | |
αvβ6 | (68)Ga-RGD | NCT05275699 | Imaging agent | 2022-03-11 | Phase I | |
Keloid | αvβ3 | PLN-74809 | NCT04072315; NCT04396756; NCT04480840; NCT04565249 | Small molecule | 2019-08-28 2020-05-21 2020-07-21 2020-09-25 | Phase II |
Primary sclerosing cholangitis/idiopathic pulmonary fibrosis/acute respiratory distress syndrome | αvβ1; αvβ6 | BIIB-107 | NCT04593121 | Small molecule | 2020-10-19 | Phase I |
HIV | α4β7 | OS2966 | NCT04608812 | Antibody | 2020-10-29 | Phase I |
Multiple sclerosis | α4 | Pagantangentide | CTR20210520 | Small molecule | 2021-04-01 | Phase I |
